22 completed, 4 active not recruiting, 3 recruiting, 2 unknown. 9 Phase 2, 9 Phase 4, 8 Phase 3, 3 Not applicable, 3 Phase 1.
Follow Yellow Fever Vaccine: new trials by email Literature Review of Yellow Fever Vaccine trials Research Report on Yellow Fever Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Improving Vaccine Protection for Adults AS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur), Placebo (NaCl 09%, 0.5mL) - Immune System Responses and Trained Immunity After AS01 Administration, Healthy Adult | Phase 2 | Recruiting | Singapore General Hospital | 40 | 2025-11-06 | 2026-06-15 |
| Phase 3 Single Arm, Open Study on vYF in Adults Yellow fever vaccine (live) - Yellow Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 254 | 2025-10-23 | 2026-02-03 |
| A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population Yellow fever vaccine (live), Measles, combinations with mumps and rubella, live attenuated - Yellow Fever Immunization | Phase 3 | Recruiting | Sanofi | 2440 | 2025-07-11 | 2026-10-14 |
| Infant Malaria Vaccine Schedule Optimization R21 Matrix-M (R21/MM) Malaria Vaccine, Placebo, Hexavalent Vaccine - Malaria Vaccines, Malaria (Plasmodium Falciparum) | Phase 2 | Active not recruiting | PATH | 975 | 2025-05-30 | 2026-09-29 |
| Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults Yellow fever vaccine (live), YF vaccine (live) - Yellow Fever Immunization | Phase 3 | Completed | Sanofi | 640 | 2025-05-22 | 2026-02-02 |
| Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months Measles-Rubella vaccine (Live) I.P. (Freeze Dried) of M/s. Zydus Lifesciences Ltd, Yellow fever Vaccine (WHO prequalified) - Measles, Rubella | Phase 3 | Not yet recruiting | International Centre for Diarrhoeal Disease Research, Bangladesh | 1530 | 2025-04-01 | 2025-02-07 |
| Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months SIBP MMR Vaccine, GSK MMR Vaccine (PRIORIX), Yellow Fever Vaccine (Stamaril) - Measles-Mumps-Rubella | Phase 3 | Completed | Shanghai Institute Of Biological Products | 1200 | 2024-06-28 | 2026-01-08 |
| A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants iNTS-GMMA Dose C, iNTS-GMMA Dose B, iNTS-GMMA Dose A - Salmonella Infections | Phase 2 | Completed | GlaxoSmithKline | 180 | 2024-01-15 | 2026-09-21 |
| Antibiotics and Vaccine Immune Responses Study BCG vaccine, Yellow Fever vaccine, Vancomycin Oral Capsule - Vaccine Response Impaired | Phase 4 | Recruiting | South Australian Health and Medical Research Institute | 348 | 2023-11-23 | 2026-09-17 |
| Yellow Fever Human Infection Model With YF-17D Yellow Fever Vaccine - Yellow Fever | Not applicable | Unknown | Leiden University Medical Center | 30 | 2023-02-17 | 2023-06-13 |
| Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine - Yellow Fever | Phase 2 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 690 | 2021-10-07 | 2026-06-01 |
| Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine - Yellow Fever, Healthy Volunteers | Phase 2 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 568 | 2021-07-01 | 2026-09-03 |
| Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine Yellow Fever Vaccine - Yellow Fever Vaccination Reaction | Phase 4 | Completed | US Army Medical Research Institute of Infectious Diseases | 88 | 2021-06-07 | 2026-04-07 |
| The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination Yellow Fever Vaccine - Yellow Fever | Phase 1 / Phase 2 | Completed | University of Minnesota | 43 | 2020-07-01 | 2025-10-07 |
| Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine - Yellow Fever (Healthy Volunteers) | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 73 | 2020-01-15 | 2025-09-22 |
| Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine Yellow fever vaccine, Institut Pasteur - Yellow Fever | Phase 4 | Completed | University of Oxford | 900 | 2019-11-11 | 2024-02-09 |
| Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination Yellow Fever Vaccine - Healthy, Cytotoxicity | Phase 4 | Unknown | University of Aarhus | 60 | 2019-10-08 | 2025-03-27 |
| Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine Yellow fever vaccine, Deuterium (70% enriched 2H2O) labeled water - Yellow Fever | Phase 4 | Completed | Sri Edupuganti | 27 | 2019-04-15 | 2025-04-29 |
| Yellow Fever Vaccine in Patients With Rheumatic Diseases Yellow Fever vaccine (17D) - Systemic Lupus, Rheumatoid Arthritis | Not applicable | Completed | University of Sao Paulo General Hospital | 600 | 2018-01-31 | 2019-04-26 |
| Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) Stamaril, Sanofi Pasteur, Yellow fever vaccine, Bio-Manguinhos, Yellow fever vaccine, Institut Pasteur - Yellow Fever | Phase 4 | Completed | Epicentre | 1630 | 2017-11-06 | 2022-02-01 |
Showing 20 of 32. Sign in to see all of them.
Yellow Fever (18) · Malaria, Falciparum (3) · Dengue (2) · Encephalitis, Japanese (2) · Malaria (2) · Measles (2) · Rubella (2) · Severe Dengue (2) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Dermatomyositis (1) · Flavivirus Infections (1) · Granulomatosis with Polyangiitis (1) · Hepatitis B (1) · Meningitis, Meningococcal (1)
Sanofi Pasteur, a Sanofi Company (6) · GlaxoSmithKline (3) · Emory University (2) · PATH (2) · Sanofi (2) · Singapore General Hospital (2) · Epicentre (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Leiden University Medical Center (1) · Novartis (1) · Rockefeller University (1) · Shanghai Institute Of Biological Products (1) · South Australian Health and Medical Research Institute (1) · Sri Edupuganti (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1)
United States (10) · Ghana (3) · Kenya (3) · Singapore (3) · Uganda (3) · Brazil (2) · Burkina Faso (2) · Germany (2) · Australia (1) · Bangladesh (1) · Colombia (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1)
Amit Singhal, B.Sc., M.Sc., Ph.D. (1) · Anna HE Roukens, MD PhD (1) · Brad R Rosenberg, MD, PhD (1) · Candice Y.Y. Chan, MBChB, MRCP (1) · David J Lewis (1) · David Lynn (1) · Eduardo Sergio S Sousa, MD (1) · Eloisa Bonfa, MD, PhD (1) · Jenny Low Guek Hong (1) · Jesper D Gunst, MD (1) · Mark J. Mulligan, MD (1) · Philip Bejon, PhD (1)
PMID 31984244, PMID 19933869, PMID 20735271, PMID 21782519, PMID 23208880, PMID 23962071, PMID 24873986, PMID 25308927, PMID 25872531, PMID 25885325, PMID 27490698, PMID 29659924, PMID 30241510, PMID 31889148, PMID 33422245, PMID 34843469, PMID 37127045, PMID 37127047, PMID 38567951, PMID 39293214, PMID 39970397, PMID 41544642, PMID 41950474, PMID 42463194
U19AI057266 (2), 2014 (1), U01AI141981 (1), U19AI111825 (1)